Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

被引:0
|
作者
Ito, Mamoru [1 ]
Okumura, Yuta [2 ]
Nio, Kenta [3 ]
Baba, Eishi [4 ]
Ozaki, Yukinori [5 ]
Nishio, Hiroshi [6 ]
Ichihara, Eiki [7 ]
Miura, Yuji [8 ]
Endo, Makoto [9 ]
Yano, Shingo [10 ]
Maruyama, Dai [11 ]
Yoshinami, Tetsuhiro [12 ]
Susumu, Nobuyuki [13 ]
Takekuma, Munetaka [14 ]
Motohashi, Takashi [15 ]
Ochi, Nobuaki [16 ]
Kubo, Toshio [17 ]
Uchino, Keita [18 ]
Kimura, Takahiro [19 ]
Kamiyama, Yutaro [20 ]
Nakao, Shinji [21 ]
Tamura, Shinobu [22 ]
Nishimoto, Hitomi [23 ]
Kato, Yasuhisa [24 ]
Sato, Atsushi [25 ]
Takano, Toshimi [5 ]
Tsuchihashi, Kenji [1 ]
机构
[1] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, 3-1-1 Maidashi,Higashi ku, Fukuoka 8128582, Japan
[2] NHO Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan
[3] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Oncol & Social Med, Fukuoka, Japan
[5] Japanese Fdn Canc Res, Dept Breast Med Oncol, Canc Inst Hosp, Tokyo, Japan
[6] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan
[7] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[8] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[9] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan
[10] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol Hematol, Tokyo, Japan
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan
[12] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan
[13] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan
[14] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka, Japan
[15] Tokyo Womens Med Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan
[16] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan
[17] Okayama Univ Hosp, Dept Allergy & Resp Med, Okayama, Japan
[18] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan
[19] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan
[20] Jikei Univ, Sch Med, Dept Clin Oncol Hematol, Tokyo, Japan
[21] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Kanazawa, Ishikawa, Japan
[22] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan
[23] Okayama Univ Hosp, Dept Nursing, Okayama, Japan
[24] Shonan Univ Med Sci, Fac Pharmaceut Sci, Dept Drug Informat, Kamakura, Kanagawa, Japan
[25] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Aomori, Japan
关键词
G-CSF; Febrile neutropenia; Digestive system tumor; FEBRILE NEUTROPENIA; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; OPEN-LABEL; PHASE-III; CANCER; RECOMMENDATIONS; PEGFILGRASTIM; FOLFIRINOX; GEMCITABINE;
D O I
10.1007/s10147-024-02502-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundGranulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology.MethodsThis systematic review addressed two main clinical questions (CQ): CQ1: "Is primary prophylaxis with G-CSF effective in chemotherapy?", and CQ2: "Is increasing the intensity of chemotherapy with G-CSF effective?" We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations.ResultsAfter two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records.ConclusionThe use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.
引用
收藏
页码:689 / 699
页数:11
相关论文
共 50 条
  • [1] Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
    Hirose, Takeshi
    Ito, Mamoru
    Tsuchihashi, Kenji
    Ozaki, Yukinori
    Nishio, Hiroshi
    Ichihara, Eiki
    Miura, Yuji
    Yano, Shingo
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Endo, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1081 - 1087
  • [2] Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
    Shoji Kimura
    Keisuke Shigeta
    Shingo Tamura
    Keita Uchino
    Takahiro Kimura
    Yukinori Ozaki
    Hiroshi Nishio
    Kenji Tsuchihashi
    Eiki Ichihara
    Makoto Endo
    Shingo Yano
    Dai Maruyama
    Tetsuhiro Yoshinami
    Nobuyuki Susumu
    Munetaka Takekuma
    Takashi Motohashi
    Mamoru Ito
    Eishi Baba
    Nobuaki Ochi
    Toshio Kubo
    Yutaro Kamiyama
    Shinji Nakao
    Shinobu Tamura
    Hitomi Nishimoto
    Yasuhisa Kato
    Atsushi Sato
    Toshimi Takano
    Yuji Miura
    International Journal of Clinical Oncology, 2024, 29 : 559 - 563
  • [3] Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
    Kimura, Shoji
    Shigeta, Keisuke
    Tamura, Shingo
    Uchino, Keita
    Kimura, Takahiro
    Ozaki, Yukinori
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Endo, Makoto
    Yano, Shingo
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Miura, Yuji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 559 - 563
  • [4] Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
    Hirose, Takeshi
    Ito, Mamoru
    Tsuchihashi, Kenji
    Ozaki, Yukinori
    Nishio, Hiroshi
    Ichihara, Eiki
    Miura, Yuji
    Yano, Shingo
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Endo, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1067 - 1073
  • [5] Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
    Tsuchihashi, Kenji
    Ito, Mamoru
    Okumura, Yuta
    Nio, Kenta
    Ozaki, Yukinori
    Nishio, Hiroshi
    Ichihara, Eiki
    Miura, Yuji
    Endo, Makoto
    Yano, Shingo
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Baba, Eishi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 700 - 705
  • [6] Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
    Tomoya Maeda
    Yuho Najima
    Yutaro Kamiyama
    Shinji Nakao
    Yukinori Ozaki
    Hiroshi Nishio
    Kenji Tsuchihashi
    Eiki Ichihara
    Yuji Miumra
    Makoto Endo
    Dai Maruyama
    Tatsuhiro Yoshinami
    Nobuyuki Susumu
    Munetaka Takekuma
    Takashi Motohashi
    Mamoru Ito
    Eishi Baba
    Nobuaki Ochi
    Toshio Kubo
    Keita Uchino
    Takahiro Kimura
    Shinobu Tamura
    Hitomi Nishimoto
    Yasuhisa Kato
    Atsushi Sato
    Toshimi Takano
    Shingo Yano
    International Journal of Clinical Oncology, 2024, 29 : 535 - 544
  • [7] Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
    Maeda, Tomoya
    Najima, Yuho
    Kamiyama, Yutaro
    Nakao, Shinji
    Ozaki, Yukinori
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Miumra, Yuji
    Endo, Makoto
    Maruyama, Dai
    Yoshinami, Tatsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Yano, Shingo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 535 - 544
  • [8] Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
    Eiki Ichihara
    Nobuaki Ochi
    Go Makimoto
    Kenichiro Kudo
    Daijiro Harada
    Yukinori Ozaki
    Hiroshi Nishio
    Kenji Tsuchihashi
    Yuji Miura
    Makoto Endo
    Shingo Yano
    Dai Maruyama
    Tetsuhiro Yoshinami
    Nobuyuki Susumu
    Munetaka Takekuma
    Takashi Motohashi
    Mamoru Ito
    Eishi Baba
    Keita Uchino
    Takahiro Kimura
    Yutaro Kamiyama
    Shinji Nakao
    Shinobu Tamura
    Hitomi Nishimoto
    Yasuhisa Kato
    Atsushi Sato
    Toshimi Takano
    Toshio Kubo
    International Journal of Clinical Oncology, 2024, 29 : 355 - 362
  • [9] Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
    Ichihara, Eiki
    Ochi, Nobuaki
    Makimoto, Go
    Kudo, Kenichiro
    Harada, Daijiro
    Ozaki, Yukinori
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Miura, Yuji
    Endo, Makoto
    Yano, Shingo
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Kubo, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (04) : 355 - 362
  • [10] Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022
    Nozawa, Kazuki
    Ozaki, Yukinori
    Yoshinami, Tetsuhiro
    Yokoe, Takamichi
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Miura, Yuji
    Endo, Makoto
    Yano, Shingo
    Maruyama, Dai
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1074 - 1080